Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) announced FDA clearance on February 12, 2021, for its gammaCore device, now allowing its use in treating migraines in adolescents aged 12 to 17. This label expansion covers acute and preventive treatment for various headache types. With an estimated 10% of school-age children experiencing migraines, this development positions gammaCore as a unique non-pharmaceutical treatment option. The clearance supports prior trials showing significant effectiveness in migraine management without acute medication reliance.
On February 11, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the completion of patient enrollment in its SAVIOR-1 study, which evaluates non-invasive vagus nerve stimulation (nVNS) for COVID-19 patients experiencing respiratory symptoms. Conducted in Valencia, Spain, the trial enrolled 110 patients aged 18 and older, randomized to receive either nVNS with standard care or standard care alone. The study aims to assess clinical events, safety, and proinflammatory cytokine levels, with preliminary results expected soon and full results in a peer-reviewed publication later this year.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed paper in Colorectal Disease, detailing a study on non-invasive vagus nerve stimulation (nVNS) for treating ileus after colorectal surgery. Conducted at St. James’s University Hospital with 40 subjects, the trial aimed to assess safety and feasibility. Results indicated nVNS was safe and improved several recovery metrics, such as reduced morphine use by 25.6% post-surgery. Future studies, including the TRANSIT study with 140 patients, aim to explore nVNS's potential further.
electroCore (Nasdaq: ECOR), a bioelectronic medicine company, will participate in a fireside chat at the BTIG Virtual MedTech Conference from February 17-19, 2021. The chat is scheduled for February 17 at 12:30 PM ET. A live webcast will be available on the company's website. The company focuses on non-invasive vagus nerve stimulation therapy to treat conditions such as cluster headaches and migraines.
electroCore (Nasdaq: ECOR) announced that gammaCore Sapphire (nVNS) is included in NHS England's new MedTech Funding Mandate Policy 2021/22, effective April 1, 2021. This policy supports NHS commissioners and providers in adopting NICE-approved technologies to enhance patient outcomes. It emphasizes that gammaCore could save the NHS up to £4,561,223 over five years. The policy aims for effective, affordable, and cost-saving innovations, transitioning from shorter renewal cycles to more stable reimbursement structures.
electroCore, Inc. (Nasdaq: ECOR) announced an agreement with RSK Medical Inc. to distribute its gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Canada. This partnership aims to provide treatment for patients with primary headache disorders, particularly migraines and cluster headaches. The agreement, with a three-year initial term, includes minimum purchase commitments. Both companies emphasize their commitment to improving patient access to innovative therapies.
electroCore, Inc. (Nasdaq: ECOR) announced that Health Improvement Scotland has published a Scottish Health Technology Group adaptation for NHS Scotland regarding the use of gammaCore for cluster headache treatment. This recommendation supports NICE guidelines from 2019, stating gammaCore can reduce attack frequency and intensity, improving patients' quality of life and saving £450 per patient in the first year. The adaptation allows for a three-month trial of gammaCore in NHS Scotland. The company aims to expand access to its treatment for cluster headache patients.
electroCore, Inc. (Nasdaq: ECOR) announced that the Centers for Medicare and Medicaid Services (CMS) published a new HCPCS code K1020 for its gammaCore Sapphire™ D device, effective April 1, 2021. This non-invasive vagus nerve stimulator code aims to enhance patient access to gammaCore therapy, which treats primary headache conditions. The decision reflects CMS’s recognition of the clinical and economic benefits of the gammaCore treatment, positioning the company for broader coverage opportunities.
electroCore (Nasdaq: ECOR) announced expected full-year 2020 revenue between $3.3M and $3.5M, reflecting over 40% growth from 2019's $2.4M. Q4 2020 net cash usage was $3.7M, better than the $4M guidance, and cash reserves at year-end totaled $22.6M. The company continues initiatives in COVID-19 and opioid use disorder treatments, alongside favorable data from the PREMIUM II migraine study. Expansion efforts included distribution agreements in Eastern Europe and government channels, despite challenges posed by COVID-19. Management expresses optimism for future growth opportunities.
electroCore, Inc. (Nasdaq: ECOR) has partnered with Pro Medical Baltic UAB to exclusively distribute its gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) therapy for headache disorders in Eastern Europe, including Lithuania, Latvia, Belarus, Kazakhstan, and Ukraine. The three-year agreement aims to enhance market access for gammaCore's treatment of cluster headaches and migraines. Pro Medical Baltic has experience in neuromodulation and a robust network of physicians, which is expected to benefit the introduction of nVNS therapy in the region.